Medite Cancer Diagnostics's market cap is currently ―. The company's EPS TTM is $; its P/E ratio is ―; Medite Cancer Diagnostics is scheduled to report earnings on August 14, 2017, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Sep 18	Jun 18	Mar 18	Dec 17	Sep 17
Income Statement	-
Total Revenue	$ 2.39M	$ 2.27M	$ 1.50M	$ 1.96M	$ 1.69M
Gross Profit	$ 1.47M	$ 1.06M	$ 335.00K	$ -936.00K	$ 369.00K
EBIT	$ -78.00K	$ -19.00K	$ -960.00K	$ -2.76M	$ -1.41M
EBITDA	$ -16.00K	$ 49.00K	$ -889.00K	$ -2.68M	$ -1.29M
Net Income Common Stockholders	$ -757.00K	$ -586.00K	$ -1.43M	$ -2.65M	$ -1.63M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 90.00K	$ 47.00K	$ 153.00K	$ 73.00K	$ 1.65M
Total Assets	$ 17.65M	$ 16.61M	$ 16.41M	$ 15.96M	$ 19.03M
Total Debt	$ 6.05M	$ 5.77M	$ 5.56M	$ 5.29M	$ 5.01M
Net Debt	$ 5.96M	$ 5.72M	$ 5.41M	$ 5.22M	$ 3.35M
Total Liabilities	$ 11.21M	$ 10.50M	$ 10.46M	$ 10.18M	$ 11.01M
Stockholders Equity	$ 6.44M	$ 6.10M	$ 5.94M	$ 5.78M	$ 8.02M
Cash Flow	-
Free Cash Flow	$ -832.00K	$ -1.02M	$ -1.64M	$ -1.80M	$ -479.00K
Operating Cash Flow	$ -821.00K	$ -1.01M	$ -1.64M	$ -1.71M	$ -463.00K
Investing Cash Flow	$ -11.00K	$ -2.00K	$ -2.00K	$ -91.00K	$ -16.00K
Financing Cash Flow	$ 899.00K	$ 887.00K	$ 1.43M	$ -591.00K	$ 2.38M

Currency in USD

Medite Cancer Diagnostics Earnings and Revenue History

Income Statement >

Medite Cancer Diagnostics Debt to Assets

Balance Sheet >

Medite Cancer Diagnostics Cash Flow

Cash Flow >

Medite Cancer Diagnostics Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing